BEIJING--(BUSINESS WIRE)--Deep Breeze Ltd, the innovator in vibration response imaging (VRI™) technology, today announced that the State Food and Drug Administration (SFDA) of the People’s Republic of China has approved the registration of the VRIxp™ device. VRIxp™ is a non-invasive, radiation-free imaging system that creates dynamic functional imaging of the lungs, it was approved by SFDA for assisting physicians to diagnose and manage patients suffering from respiratory complaints. This announcement marks Deep Breeze’s official marketing approval of the VRIxp™ device in China. The VRIxp™ system will be marketed to specialists and physicians at hospitals, clinics and screening centers.
